Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Umbilical Cord Blood

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    76 result(s) found for: Umbilical Cord Blood. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2010-021783-15 Sponsor Protocol Number: Version 1.0 Start Date*: 2010-12-31
    Sponsor Name:Guys and St Thomas' NHS Foundation Trust
    Full Title: Ropivacaine 0.75% versus Levobupivacaine 0.5% for conversion of labour epidural to surgical anaesthesia for emergency Caesarean section. (RoLe Trial)
    Medical condition: Conversion of labour epidural to surgical anaesthesia for emergency Caesarean section
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006924 Caesarean section LLT
    12.1 10054375 Epidural anesthesia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000145-40 Sponsor Protocol Number: versión2.febrero2017 Start Date*: 2017-09-20
    Sponsor Name:montserrat zamora brito
    Full Title: Use of acupuncture for the reduction of hospital admissions in the induction of labor due to chronologically prolonged gestation. ACUPUNT STUDY
    Medical condition: This Clinical Trial will evaluate the efficacy and safety of acupuncture to promote labor in pregnant women who need an induction at birth and thus be able to give answers to all these women who a...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001038-17 Sponsor Protocol Number: MK-8228-040 Start Date*: 2019-05-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in ...
    Medical condition: Cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003450-22 Sponsor Protocol Number: P-105-303 Start Date*: 2022-03-08
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar...
    Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002727-38 Sponsor Protocol Number: OMS721-HCT-002 Start Date*: Information not available in EudraCT
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant...
    Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10064477 Coagulopathies and bleeding diatheses (excl thrombocytopenic) HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    20.0 10005329 - Blood and lymphatic system disorders 10053567 Coagulopathies HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Completed) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001910-33 Sponsor Protocol Number: AGAL02603 Start Date*: 2007-12-05
    Sponsor Name:Genzyme Europe BV
    Full Title: A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016016 Fabry's disease PT
    Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-002502-74 Sponsor Protocol Number: NEU-01-02-01 Start Date*: 2012-02-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004526-28 Sponsor Protocol Number: BMT-CTN#1101 Start Date*: 2015-06-17
    Sponsor Name:National Institutes of Health/National Heart, Lung and Bood Institute
    Full Title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow ...
    Medical condition: patients eligible for a hematopoietic stem cell transplantation with a diagnosis of: 1)Acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia, or Burkitt’s lymphoma in remission. 2)Lym...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    16.1 100000004864 10024330 Leukemia acute LLT
    16.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10006596 Burkitt's lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000994-96 Sponsor Protocol Number: 214725 Start Date*: 2021-07-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in hi...
    Medical condition: High risk pregnant women (prevention of RSV-associated lower respiratory tract illnesses (LRTIs) in infants)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) ES (Temporarily Halted) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005508-33 Sponsor Protocol Number: MC-FludT.16/NM Start Date*: 2014-09-29
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients ...
    Medical condition: Male and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary imm...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10021606 Inborn errors of metabolism NEC HLT
    20.0 100000004870 10036700 Primary immunodeficiency syndromes HLT
    20.0 100000004850 10018903 Haemoglobinopathies congenital HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004972-49 Sponsor Protocol Number: CLFG316X2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass...
    Medical condition: Transplant associated microangiopathy (TAM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10050444 Microangiopathy NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005159-14 Sponsor Protocol Number: GC P#02.01.001 Start Date*: 2008-04-15
    Sponsor Name:Gamida Cell-Teva Joint Venture Ltd.
    Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ...
    Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10009015 Chronic myeloid leukemia LLT
    9.1 10001690 ALL LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-006178-86 Sponsor Protocol Number: EBMT-LE-0601 Start Date*: 2007-08-03
    Sponsor Name:European group for Blood and Marrow Transplantation
    Full Title: A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease
    Medical condition: patients with newly diagnosed (first episode) extensive chronic Graft versus Host Disease (cGvHD) post allogeneic transplantation for any primary diagnosis
    Disease: Version SOC Term Classification Code Term Level
    7 10018651 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005692-18 Sponsor Protocol Number: 1263-300 Start Date*: 2007-07-24
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of Maribavir to prevent cytomegalovirus disease in recipients of allogeneic stem cell transplants.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005105-27 Sponsor Protocol Number: P-105-202 Start Date*: 2022-05-02
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV...
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:10:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA